Praxis Precision Medicines, Inc.(PRAX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PRAX Praxis Precision Medicines, Inc.

已收盘 07-20 16:00:00 EDT

304.43

-9.98

-3.17%

盘后304.43

+0.000.00%

19:37 EDT

最高325.66	最低304.19	成交量23.33万
今开315.00	昨收314.41	日振幅6.83%
总市值84.79亿	流通市值73.10亿	总股本2,785万
成交额7,246万	换手率0.97%	流通股本2,401万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PRAX","market":"US","secType":"STK","nameCN":"Praxis Precision Medicines, Inc.","latestPrice":304.43,"timestamp":1784577600000,"preClose":314.41,"halted":0,"volume":233348,"hourTrading":{"tag":"盘后","latestPrice":304.43,"preClose":304.43,"latestTime":"19:37 EDT","volume":2628,"amount":800207.97,"timestamp":1784590667912,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.03174199293915594,"floatShares":24012900,"shares":27850833,"eps":-13.34879,"marketStatus":"已收盘","change":-9.98,"latestTime":"07-20 16:00:00 EDT","open":315,"high":325.6575,"low":304.19,"amount":72462907.8584,"amplitude":0.068279,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-13.34879,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1784620800000},"marketStatusCode":5,"adr":0,"listingDate":1602820800000,"exchange":"NASDAQ","adjPreClose":314.41,"preHourTrading":{"tag":"盘前","latestPrice":315,"preClose":314.41,"latestTime":"09:25 EDT","volume":162,"amount":51412.9194,"timestamp":1784553900060,"change":0.59,"changeRate":0.001877,"amplitude":0.015903},"postHourTrading":{"tag":"盘后","latestPrice":304.43,"preClose":304.43,"latestTime":"19:37 EDT","volume":2628,"amount":800207.97,"timestamp":1784590667912,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.772423,"impliedVol":0.7319,"impliedVolPercentile":0.3785},"requestUrl":"/m/hq/s/PRAX","defaultTab":"news","newsList":[{"id":"1150710040","title":"Praxis Precision Medicines与Remagine Labs宣布战略合作，开发治疗特发性震颤的透皮乌利沙卡他胺","url":"https://stock-news.laohu8.com/highlight/detail?id=1150710040","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150710040?lang=zh_cn&edition=full","pubTime":"2026-07-07 20:02","pubTimestamp":1783425763,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines与Remagine Labs已达成一项战略合作，旨在共同开发用于治疗特发性震颤（Essential Tremor）的透皮制剂乌利沙卡他胺（Ulixacaltamide）。此次合作将结合双方在精准医疗与创新药物递送技术方面的专长，推进该疗法的研发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE0002141913.USD","LU0320765992.SGD","PRAX","LU0889565916.HKD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU0109394709.USD","IBRN","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145729432","title":"异动解读｜Praxis Precision Medicines盘中下跌5.15%，FDA延长Relutrigine审评期三个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1145729432","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145729432?lang=zh_cn&edition=full","pubTime":"2026-07-02 01:19","pubTimestamp":1782926376,"startTime":"0","endTime":"0","summary":"7月2日，Praxis Precision Medicines盘中下跌5.15%，报317.56美元/股，成交额8460.42万美元。消息面上，FDA近日宣布将公司核心药物Relutrigine用于SCN2A及SCN8A相关发育性癫痫脑病的新药申请审评期延长三个月。此前FDA为该药设定的PDUFA目标行动日期为9月27日，延期意味着获批时间节点进一步推迟，市场对公司商业化进度预期承压。Praxis Precision Medicines是一家临床阶段生物制药公司，专注于将遗传学见解转化为以神经元失衡为特征的中枢神经系统疾病疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174960852","title":"Praxis Precision Medicines：FDA将Relutrigine用于SCN2A及SCN8A相关发育性癫痫脑病的NDA审评期延长三个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1174960852","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174960852?lang=zh_cn&edition=full","pubTime":"2026-06-30 04:33","pubTimestamp":1782765196,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines公司宣布，美国食品药品监督管理局（FDA）已将其药物Relutrigine用于治疗SCN2A与SCN8A相关发育性癫痫脑病的新药申请审评期延长了三个月。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","IE0002141913.USD","BK4139","IE00BJT1NW94.SGD","LU0320765992.SGD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","PRAX","LU0109394709.USD","LU0889565916.HKD","IE0009355771.USD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166571521","title":"异动解读｜Praxis Precision Medicines盘中上涨5.02%，报283.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1166571521","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166571521?lang=zh_cn&edition=full","pubTime":"2026-06-19 02:31","pubTimestamp":1781807488,"startTime":"0","endTime":"0","summary":"6月19日，Praxis Precision Medicines盘中上涨5.02%，报283.57美元/股，成交额5697.49万美元。Praxis Precision Medicines所在的生物科技行业中，个股表现分化，其中CervoMed涨7.14%，Moderna, Inc.涨3.47%，安进跌1.8%，艾伯维公司跌2.05%，吉利德科学跌1.96%。Praxis Precision Medicines是一家临床阶段的生物制药公司，致力于将遗传见解转化为中枢神经系统治疗方法的发展，聚焦以神经元失衡为特征的疾病领域。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133048713","title":"异动解读｜Praxis Precision Medicines盘中上涨5.29%，报268.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133048713","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133048713?lang=zh_cn&edition=full","pubTime":"2026-06-17 21:55","pubTimestamp":1781704539,"startTime":"0","endTime":"0","summary":"6月17日，Praxis Precision Medicines盘中上涨5.29%，报268.78美元/股，成交额2114.31万美元。Praxis Precision Medicines所在的生物科技行业中，个股表现分化，其中uniQure N.V.涨69.66%，Azitra Inc涨48.13%，Lunai Bioworks涨59.58%，PTC Therapeutics Inc.涨7.24%，吉利德科学涨0.12%。Praxis Precision Medicines是一家临床阶段的生物制药公司，致力于将遗传见解转化为中枢神经系统治疗方法的发展，聚焦以神经元失衡为特征的疾病领域。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170846873","title":"异动解读｜Praxis Precision Medicines盘中上涨5.81%，报262.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1170846873","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170846873?lang=zh_cn&edition=full","pubTime":"2026-06-12 22:01","pubTimestamp":1781272890,"startTime":"0","endTime":"0","summary":"6月12日，Praxis Precision Medicines盘中上涨5.81%，报262.38美元/股，成交额939.52万美元。Praxis Precision Medicines所在的生物科技行业中，个股表现分化，其中Nuvalent跌0.16%，艾伯维公司涨0.70%，安进跌0.38%，吉利德科学跌0.95%，Insmed跌0.24%。Praxis Precision Medicines是一家临床阶段的生物制药公司，致力于将遗传见解转化为中枢神经系统治疗方法的发展，聚焦以神经元失衡为特征的疾病领域。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198928830","title":"异动解读｜Praxis Precision Medicines盘中下跌5.17%，核心癫痫临床试验主要终点失败影响持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1198928830","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198928830?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:30","pubTimestamp":1780583405,"startTime":"0","endTime":"0","summary":"6月4日，Praxis Precision Medicines盘中下跌5.17%，报272.1美元/股，成交额6508.06万美元。尽管试验达到50%应答率的关键次要终点，30毫克剂量组癫痫发作减少更为显著，且核心药物Vormatrigine因不良事件停药率低于10%、耐受性良好，股价曾出现短暂反弹，但主要终点失败对公司核心管线构成的重大挑战仍在持续压制市场信心。对于临床阶段生物制药公司而言，关键试验主要终点未达标意味着后续开发路径面临高度不确定性，市场情绪尚未完全消化该利空影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126025209","title":"异动解读｜Praxis Precision Medicines盘中上涨5.31%，核心癫痫试验次要终点积极信号推动反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1126025209","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126025209?lang=zh_cn&edition=full","pubTime":"2026-06-03 22:31","pubTimestamp":1780497086,"startTime":"0","endTime":"0","summary":"6月3日，Praxis Precision Medicines盘中上涨5.31%，报271.78美元/股，成交额4320.95万美元。消息面上，公司此前公布Power1研究结果，虽针对难治性局灶性发作癫痫的主要终点未达标，股价一度大跌逾15%，但试验达到50%应答率的关键次要终点，30毫克剂量组癫痫发作减少更为显著，同时核心药物Vormatrigine因不良事件停药率低于10%，耐受性良好。市场在消化主要终点失败冲击后，次要终点积极数据及良好安全性为后续临床开发保留路径，推动股价持续反弹。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173943333","title":"异动解读｜Praxis Precision Medicines盘前上涨5.7%，核心癫痫试验次要终点积极信号推动反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1173943333","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173943333?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:03","pubTimestamp":1780473786,"startTime":"0","endTime":"0","summary":"6月3日，Praxis Precision Medicines盘前上涨5.7%，报273.0美元/股，成交额6.37万美元。消息面上，公司此前公布Power1研究结果，虽针对难治性局灶性发作癫痫的主要终点未达标，盘中一度大跌15.36%，但试验达到50%应答率的关键次要终点，30毫克剂量组癫痫发作减少更为显著，同时核心药物Vormatrigine因不良事件停药率低于10%，耐受性良好。市场在消化主要终点失败冲击后，次要终点积极数据及良好安全性为后续临床开发保留路径，推动股价持续反弹。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116005873","title":"异动解读｜Praxis Precision Medicines夜盘上涨7.39%，核心癫痫试验次要终点积极信号推动反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1116005873","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116005873?lang=zh_cn&edition=full","pubTime":"2026-06-03 11:29","pubTimestamp":1780457359,"startTime":"0","endTime":"0","summary":"6月3日，Praxis Precision Medicines夜盘上涨7.39%，报277.15美元/股，成交额7.77万美元。消息面上，公司此前公布Power1研究结果，虽针对难治性局灶性发作癫痫的主要终点未达标，盘中一度大跌15.36%，但试验达到50%应答率的关键次要终点，30毫克剂量组癫痫发作减少更为显著，同时Vormatrigine因不良事件停药率低于10%，耐受性良好。市场在消化主要终点失败冲击后，次要终点积极数据及良好安全性推动股价出现技术性反弹。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129219975","title":"异动解读｜Praxis Precision Medicines盘后下跌8.94%，核心癫痫临床试验未达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1129219975","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129219975?lang=zh_cn&edition=full","pubTime":"2026-06-03 04:23","pubTimestamp":1780431799,"startTime":"0","endTime":"0","summary":"6月3日，Praxis Precision Medicines盘后下跌8.94%，报258.59美元/股，成交额21.2万美元。消息面上，公司宣布其针对难治性局灶性发作癫痫的Power1研究未能达到预设的主要疗效终点，这一结果对公司核心管线构成重大挑战。对于临床阶段的生物制药公司而言，关键试验主要终点未达标通常意味着后续开发路径面临高度不确定性。但次要终点的积极信号未能抵消主要终点失败带来的市场担忧，股价在盘中大跌15.36%后盘后继续走低。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182307151","title":"异动解读｜Praxis Precision Medicines盘中下跌15.36%，核心癫痫临床试验未达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1182307151","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182307151?lang=zh_cn&edition=full","pubTime":"2026-06-03 00:13","pubTimestamp":1780416798,"startTime":"0","endTime":"0","summary":"6月2日，Praxis Precision Medicines盘中下跌15.36%，报283.47美元/股，成交额2.07亿美元。消息面上，公司宣布其针对难治性局灶性发作癫痫的Power1研究未能达到预设的主要疗效终点，这一结果对公司核心管线构成重大挑战。对于临床阶段的生物制药公司而言，关键试验主要终点未达标通常意味着后续开发路径面临不确定性，市场对此反应剧烈。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177523657","title":"Praxis Precision Medicines新药Vormatrigine耐受性良好，不良事件停药率低于10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177523657","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177523657?lang=zh_cn&edition=full","pubTime":"2026-06-02 04:17","pubTimestamp":1780345035,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines公司宣布，其研发的药物Vormatrigine在临床试验中展现出良好的耐受性。数据显示，因不良事件而停止用药的患者比例被控制在10%以下，这一结果令人鼓舞。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","BK4139","IE00BJT1NW94.SGD","LU0320765992.SGD","IE0002141913.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","PRAX","IE00B2B36J28.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146218009","title":"Praxis Precision Medicines达到次要终点50%应答率 30毫克剂量组癫痫发作减少更显著","url":"https://stock-news.laohu8.com/highlight/detail?id=1146218009","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146218009?lang=zh_cn&edition=full","pubTime":"2026-06-02 04:17","pubTimestamp":1780345035,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc. 宣布其临床试验达到了关键的次要终点，即50%的应答率。数据显示，在降低癫痫发作频率方面，30毫克剂量组展现出了更为显著的效果。这一发现突显了该剂量在疗效上的优势，为后续的临床开发提供了重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","PRAX","IE00BFTCPJ56.SGD","BK4139","LU0109394709.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160185701","title":"Praxis Precision Medicines公司Power1研究在难治性局灶性发作癫痫中未达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1160185701","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160185701?lang=zh_cn&edition=full","pubTime":"2026-06-02 04:17","pubTimestamp":1780345034,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines公司宣布，其针对难治性局灶性发作癫痫的Power1研究未能达到预设的主要疗效终点。该结果对公司的相关研发项目构成了挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","IE00BJT1NW94.SGD","LU0109394709.USD","PRAX","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0889565916.HKD","BK4139","IE00B2B36J28.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146879586","title":"Praxis Precision Medicines公布企业动态及2026年第一季度财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1146879586","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146879586?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:01","pubTimestamp":1778155288,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc.近日同步披露了公司最新运营进展与2026财年首季度财务报告。此次公告涵盖公司核心研发管线推进情况、关键业务里程碑及当期财务数据，为投资者提供全面战略透视。财务结果显示，公司在精准神经科学疗法领域的投入持续深化，多项临床阶段项目取得突破性进展。管理层在财报中强调，将加速推进针对遗传性癫痫疾病的创新疗法全球化布局，同时通过优化资本结构提升长期竞争力。此次季度业绩的发布，标志着Praxis在精准医疗领域战略执行进入新阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE0009355771.USD","LU0889565916.HKD","BK4139","IE00BJT1NW94.SGD","LU0320765992.SGD","PRAX","IE00B4R5TH58.HKD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172675456","title":"Praxis Precision Medicines, Inc.：FDA将Ulixacaltamide的PDUFA目标行动日期定为2027年1月29日","url":"https://stock-news.laohu8.com/highlight/detail?id=1172675456","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172675456?lang=zh_cn&edition=full","pubTime":"2026-04-14 19:30","pubTimestamp":1776166250,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已为Praxis Precision Medicines, Inc.旗下的在研药物Ulixacaltamide，设定了处方药使用者付费法案（PDUFA）的目标行动日期，定于2027年1月29日。这一日期标志着FDA完成对该药物新药申请审查的目标时间点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0109394709.USD","IE00B4R5TH58.HKD","IE0002141913.USD","LU0320765992.SGD","IE00B2B36J28.USD","IE0009355771.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","BK4139","PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132558277","title":"Praxis Precision Medicines宣布FDA受理盐酸Ulixacaltamide治疗特发性震颤的新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1132558277","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132558277?lang=zh_cn&edition=full","pubTime":"2026-04-14 19:30","pubTimestamp":1776166242,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines公司宣布，美国食品药品监督管理局（FDA）已正式受理其针对特发性震颤患者的新药申请，该申请涉及药物盐酸Ulixacaltamide。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX","LU0109394709.USD","LU0889565916.HKD","IE00B4R5TH58.HKD","IE0002141913.USD","LU0320765992.SGD","IE00BJT1NW94.SGD","BK4139","IE00B2B36J28.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158299786","title":"Praxis Precision Medicines公司：Elsunersen在最高8毫克剂量下耐受性良好，未出现药物相关严重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1158299786","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158299786?lang=zh_cn&edition=full","pubTime":"2026-04-06 20:03","pubTimestamp":1775477038,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines公司宣布，其研究药物Elsunersen在临床试验中表现出良好的耐受性。数据显示，在剂量递增至8毫克的范围内，未观察到任何与药物相关的严重不良事件。这一结果进一步支持了该候选药物的安全性特征。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","LU0320765992.SGD","LU0109394709.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","PRAX","IE00B4R5TH58.HKD","IE0009355771.USD","BK4139","IE0002141913.USD","LU0889565916.HKD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112964089","title":"Praxis精准医疗公布Elsunersen治疗SCN2A早发性发育性癫痫性脑病的Embrave试验A部分积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1112964089","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112964089?lang=zh_cn&edition=full","pubTime":"2026-04-06 20:01","pubTimestamp":1775476874,"startTime":"0","endTime":"0","summary":"Praxis精准医疗公司近日宣布，其针对SCN2A早发性发育性癫痫性脑病研发的药物Elsunersen，在Embrave临床试验的A阶段取得了积极的研究成果。该试验数据表明，Elsunersen在目标患者群体中展现出良好的治疗潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","IE00BJT1NW94.SGD","LU0109394709.USD","PRAX","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0889565916.HKD","BK4139","IE00B2B36J28.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.praxismedicines.com","stockEarnings":[{"period":"1week","weight":-0.0326},{"period":"1month","weight":0.1644},{"period":"3month","weight":-0.082},{"period":"6month","weight":-0.009},{"period":"1year","weight":4.7228},{"period":"ytd","weight":0.0667}],"compareEarnings":[{"period":"1week","weight":-0.0154},{"period":"1month","weight":0.0031},{"period":"3month","weight":0.0467},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.1835},{"period":"ytd","weight":0.09}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Praxis Precision Medicines, Inc.于2015年9月22日根据特拉华州法律成立。该公司是一家临床阶段的生物制药公司，将遗传见解转化为中枢神经系统（CNS）治疗方法的发展，CNS是以神经元失衡为特征的疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.298328},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.166549},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.160217},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.017086},{"month":5,"riseRate":0.5,"avgChangeRate":-0.087139},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.085881},{"month":7,"riseRate":0.5,"avgChangeRate":0.129836},{"month":8,"riseRate":0.4,"avgChangeRate":0.080633},{"month":9,"riseRate":0.6,"avgChangeRate":0.013557},{"month":10,"riseRate":0.6,"avgChangeRate":0.512334},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073478},{"month":12,"riseRate":0.833333,"avgChangeRate":0.206625}],"exchange":"NASDAQ","name":"Praxis Precision Medicines, Inc.","nameEN":"Praxis Precision Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Praxis Precision Medicines, Inc.(PRAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Praxis Precision Medicines, Inc.(PRAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Praxis Precision Medicines, Inc.,PRAX,Praxis Precision Medicines, Inc.股票,Praxis Precision Medicines, Inc.股票老虎,Praxis Precision Medicines, Inc.股票老虎国际,Praxis Precision Medicines, Inc.行情,Praxis Precision Medicines, Inc.股票行情,Praxis Precision Medicines, Inc.股价,Praxis Precision Medicines, Inc.股市,Praxis Precision Medicines, Inc.股票价格,Praxis Precision Medicines, Inc.股票交易,Praxis Precision Medicines, Inc.股票购买,Praxis Precision Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Praxis Precision Medicines, Inc.(PRAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Praxis Precision Medicines, Inc.(PRAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}